

---

**Date: 29<sup>th</sup> December, 2025**

**To,  
The Deputy Manager  
(Department of Corporate Services)  
BSE Limited  
P. J. Towers Dalal Street,  
Fort, Mumbai- 400001**

**Sub: Intimation Under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- "Signing of Letter of Intent".**

**Ref: Scrip Code: 512600**

**Security Id: ASTALLTD**

---

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we hereby announce that the Company has signed a Letter of Intent (LOI) with Switzerland-based Immuna Therapeutics GmbH for the exclusive India rights to next-generation CAR-T cell therapies, including TriCAR-T platforms.

The proposed collaboration covers technology transfer, localization of manufacturing, clinical development, and commercialization in India. The initiative supports Company's long-term strategy to expand into high-value advanced therapies and cell and gene therapy platforms.

Astal estimates the collaboration will generate incremental revenue of approximately ₹300 crore upon implementation, driven by rising demand for advanced oncology treatments and improved access through localized manufacturing.

The partnership positions the Company at the forefront of next-generation immuno-oncology in India while creating a scalable platform for future cell therapy programs.

The above intimation is given to you for your record, kindly take the note of the same.

Thanking You,

Yours faithfully,

**For Astal Laboratories Limited**

**Mahendra Kumar  
(Company Secretary & Compliance officer)  
Membership No.: A71224**